Document is current
Any future updates will be listed below
-
Authors
Yang, Yang https://orcid.org/0000-0003-3801-681X
Jn-Simon, Natacha https://orcid.org/0009-0006-6533-2569
He, Yonghan https://orcid.org/0000-0003-4409-4590
Sun, Chunbao
Zhang, Peiyi
Hu, Wanyi
Tian, Tian
Zeng, Huadong
Basha, Sreenivasulu
Huerta, Araceli S.
Sun, Lu-Zhe
Yin, Xian-Ming https://orcid.org/0000-0002-8576-6093
Hromas, Robert
Zheng, Guangrong https://orcid.org/0000-0002-8106-6663
Pi, Liya https://orcid.org/0000-0002-9868-7677
Zhou, Daohong https://orcid.org/0000-0002-2400-6461
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 AG063801, R01 CA242003, P30 CA054174, R01 AG063801, R01 CA242003, K01 AA024174, R01 AA028035)
Cancer Prevention and Research Institute of Texas (RP210208)
United States Department of Commerce | National Institute of Standards and Technology (60NANB24D117)
- License Information
-
More Information
Article History
Received: 2 March 2023
Accepted: 5 December 2024
First Online: 31 January 2025
Competing interests
: Y.Y., Y.H., P.Z., W.H., G.Z., L.P. and D.Z. are inventors on patents for the use of BCL-xL PROTACs as anti-tumor agents and senolytics. R.H., G.Z. and D.Z. are cofounders of and have equity in Dialectic Therapeutics, which develops BCL-xL/2 PROTACs to treat cancer. The other authors declare no competing interests.
